SAN DIEGO, Sept. 14, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that detailed results from a four-month interim analysis in an ongoing Phase 2 trial of the company’s TransVax(TM) therapeutic cytomegalovirus (CMV) DNA vaccine were presented yesterday in a late-breaker session at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC, San Francisco - September 12-15). Marissa Wilck, M.D., an infectious disease vaccine researcher at Brigham and Women’s Hospital and one of the lead investigators in the trial, presented the data. The company had previously announced summary interim results from the trial.
